Zimmer Biomet has gained regulatory approval to expand the availability of its Sidus stem-free shoulder system to the US market.
The device, which has been available in Europe since 2012, has been approved by the US Food and Drug Administration (FDA) as a total shoulder arthroplasty solution for patients with a number of bone conditions.
“Zimmer Biomet's Sidus stem-free shoulder system has been approved for use by the US Food and Drug Administration.“
Sidus is intended for users with good bone stock who are affected by osteoarthritis, post-traumatic arthrosis or focal avascular necrosis of the humeral head, or who have received previous shoulder surgeries that did not compromise the fixation.
It has been proven to help restore a patient's anatomy, preserve bone stock, and allow for improved pre- and post-operative patient outcomes. The device will launch in the US during the first quarter of the year.
Bryan Hanson, Zimmer Biomet's president and chief executive officer, said: "The addition of the Sidus system to Zimmer Biomet's US portfolio reinforces the company's leadership in the innovation of shoulder solutions."
Mr Hanson took up his new role in charge of Zimmer Biomet last month, having previously worked for Medtronic.
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices